GNCAQ
GENOCEA BIOSCIENCES INCstockOTC
genocea is harnessing the power of t cell immunity to develop life-changing vaccines and immunotherapies. while traditional immunotherapy discovery methods have largely used predictive methods to propose t cell targets, or antigens, genocea has successfully developed atlas™, its proprietary technology platform, to identify clinically relevant antigens of t cells based on actual human immune responses. genocea is currently using atlas in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by epstein-barr virus.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1M | 0.00 | 2026-10-21 | +900.00% | -536.401 |
| 3M | 0.00 | 2026-08-20 | +900.00% | -152.997 |
| 6M | 0.00 | 2026-05-21 | +900.00% | 84.233 |
| 1Y | 0.00 | 2025-11-19 | +900.00% | 26.679 |
| 2Y | 0.00 | 2024-11-21 | +900.00% | — |
| 5Y | 0.00 | 2023-05-12 | -90.00% | 84.939 |
GENOCEA BIOSCIENCES INC (OTC:GNCAQ) stock price today is $0.00, and today's volume is 804. GNCAQ is up 900.000% today. The 30 day average volume is 4,591. GNCAQ market cap is $588 with 58.78M shares outstanding.